Traders Buy Large Volume of Put Options on 23andMe (NASDAQ:ME)

23andMe Holding Co. (NASDAQ:ME) was the recipient of some unusual options trading activity on Tuesday. Stock traders purchased 2,416 put options on the stock. This represents an increase of approximately 139% compared to the average volume of 1,009 put options.

Institutional Investors Weigh In On 23andMe

Large investors have recently bought and sold shares of the business. Geode Capital Management LLC grew its stake in shares of 23andMe by 0.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,246,093 shares of the company’s stock worth $1,476,000 after buying an additional 28,252 shares in the last quarter. Leavell Investment Management Inc. bought a new position in shares of 23andMe in the 4th quarter valued at about $32,000. FNY Investment Advisers LLC purchased a new position in 23andMe in the fourth quarter worth about $26,000. MassMutual Private Wealth & Trust FSB bought a new stake in 23andMe during the fourth quarter worth approximately $40,000. Finally, Shay Capital LLC raised its position in 23andMe by 71.7% during the fourth quarter. Shay Capital LLC now owns 702,530 shares of the company’s stock valued at $2,283,000 after purchasing an additional 293,358 shares during the period. Institutional investors own 36.10% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of 23andMe in a report on Saturday, March 22nd.

23andMe Stock Down 18.4 %

Shares of 23andMe stock opened at $0.53 on Thursday. 23andMe has a twelve month low of $0.53 and a twelve month high of $12.76. The business has a 50-day moving average price of $2.38 and a 200-day moving average price of $3.83. The firm has a market cap of $14.23 million, a price-to-earnings ratio of -0.03 and a beta of 1.19.

23andMe (NASDAQ:ME) last released its quarterly earnings results on Tuesday, January 28th. The company reported ($1.02) earnings per share for the quarter. 23andMe had a negative net margin of 183.39% and a negative return on equity of 170.07%.

23andMe Company Profile

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.